American Society of Hematology

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.

Content to be used in accordance with local CPO guidelines

MDS/AML/AdvSM

MDS/AML/AdvSM

List of Presentations

CAR-T CML Early Pipeline ITP/SAA LCH MDS/AML/AdvSM MPN/GvHD PNH SCD

Midostaurin in Patients With Newly Diagnosed FLT3-Mutation Negative Acute Myeloid Leukemia: Final Results and Measurable Residual Disease Analyses From the UNIFY Trial

Cloos JJ

  • Presentation # 1303 – Poster
    December 11, 2021 | 05:30 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Efficacy and Safety of Sabatolimab in Combination With Hypomethylating Agents in Patients With Very High/High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Final Analysis From a Phase Ib Study

Brunner AM

  • Presentation # 244 – Oral
    December 11, 2021 | 02:45 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Treatment Patterns and Overall Survival in Patients With Intermediate-Risk Myelodysplastic Syndrome (MDS): A Retrospective Analysis in the Grupo Español de Síndromes Mielodisplásicos (GESMD) Spanish MDS Registry

Diez-Campelo M

  • Presentation # 2605 – Poster
    December 12, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Development and Content Validity of a Novel Myelodysplastic Syndromes Symptom Daily Diary

Vallow S

  • Presentation # 4654 – Publication Only

  • Abstract
This presentation will be available once the congress embargo lifts

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program

Zeidan AM

  • Presentation # 4669 – Publication Only

  • Abstract
This presentation will be available once the congress embargo lifts

Siremadlin (HDM201) is Well Tolerated and Demonstrates Clinical Activity in Patients With Acute Myeloid Leukemia Who Have Relapsed After Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy

Stein EM

  • Presentation # 3417 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

A Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination With Venetoclax in Acute Myeloid Leukemia or Very High/High-Risk Myelodysplastic Syndrome

Wei AH

  • Presentation # 1283 – Poster
    December 11, 2021 | 05:30 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts
View list of select presentations for this compound